Download PDF
Thromb Haemost 1992; 68(04): 407-412
DOI: 10.1055/s-0038-1646287
Original Article
Schattauer GmbH Stuttgart

The Production of a Factor X Activator by a Methylcholanthrene-Induced Rat Fibrosarcoma

Rosanna S Pangasnan
The UMDNJ-Robert Wood Johnson Medical School, Division of Hematology/Oncology, New Brunswick, NJ, USA
,
Dennis Devereux
The UMDNJ-Robert Wood Johnson Medical School, Division of Hematology/Oncology, New Brunswick, NJ, USA
,
Louis P DeCunzo
The UMDNJ-Robert Wood Johnson Medical School, Division of Hematology/Oncology, New Brunswick, NJ, USA
,
George I Karp
The UMDNJ-Robert Wood Johnson Medical School, Division of Hematology/Oncology, New Brunswick, NJ, USA
› Author Affiliations
Further Information

Publication History

Received 21 August 1991

Accepted after revision 04 May 1992

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The association between neoplasia and thrombosis has been well documented. We have studied the production of a procoagulant which is a factor X activator in a rat fibrosarcoma model. Extracts of excised tumor were assayed in a one stage clotting assay using normal and factor deficient human plasmas. The activity was not due to tissue factor, as acceleration of clotting was observed in FVII deficient plasma. No activity was noted in FX deficient plasma. The activator was capable of cleaving 125I-FX in the absence or presence of calcium. A radioimmunoassay (RIA) demonstrated a 5,100-fold increase in the levels of FX activation peptide after exposure to sarcoma extract. The FX activation occurs in the absence of calcium although the effect is greatly accelerated in the presence of 5 mM CaCl2. Using a two-stage amidolytic assay, functional activation of FX by the sarcoma was demonstrated. Inhibitor studies suggest that the sarcoma-derived procoagulant is a serine protease. The methylcholanthrene-induced rat sarcoma may serve as a useful model for investigating the regulation and effects of cancer procoagulants.

 

  • REFERENCES

  • 1 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l’Hôtel-Dieu de Paris. London, New Sydenham Society: 1865. 3 94
    Google Scholar
  • 2 Sack Jr GH, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 01-37
    CrossrefPubMedGoogle Scholar
  • 3 Hoerr SO, Harper JR. On peripheral thrombophlebitis; its occurence as a presenting symptom in malignant disease of the pancreas, biliary tract or duodenum. JAMA 1957; 164: 2033-2044
    CrossrefPubMedGoogle Scholar
  • 4 Kasimis BS, Spiers AS. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1979; 1: 159
    PubMedGoogle Scholar
  • 5 Sproul EE. Carcinoma and venous thrombosis: frequency of association of carcinoma in body or tail of pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
    PubMedGoogle Scholar
  • 6 Francis JL. Haemostasis and cancer. Med Lab Sci 1989; 46: 331-346
    PubMedGoogle Scholar
  • 7 Rickles R, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
    PubMedGoogle Scholar
  • 8 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6: 61-71
    PubMedGoogle Scholar
  • 9 Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with pulmonary embolism. Ann Intern Med 1982; 96: 556-566
    CrossrefPubMedGoogle Scholar
  • 10 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauws S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407
    CrossrefPubMedGoogle Scholar
  • 11 Pineo G, Brain MC, Gallus AS, Hirsh J, Hatton MWC, Regoeczi E. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 1974; 230: 262-270
    CrossrefPubMedGoogle Scholar
  • 12 Spar IL, Bale W, Marrack D, Dewey WC, McCardle RJ, Harper PV. 131I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer. 1967; 20: 865-870
    PubMedGoogle Scholar
  • 13 Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52
    CrossrefPubMedGoogle Scholar
  • 14 Powles TJ, Easty GC, Easty DM, Neville AM. Antimetastatic effect of aspirin. Lancet 1973; 2: 100
    PubMedGoogle Scholar
  • 15 Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-559
    CrossrefPubMedGoogle Scholar
  • 16 Gastpar H. Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approach to metastasis prophylaxis. J Med 1977; 8: 103-114
    PubMedGoogle Scholar
  • 17 Hagmar B. Experimental tumour metastases and blood coagulability. Acta Pathol Microbiol Scand 1970; 211: 05-38
    PubMedGoogle Scholar
  • 18 Kadish JL, Wenc KM, Dvorak H. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst 1983; 70: 551-557
    PubMedGoogle Scholar
  • 19 Gouault-Heilman M, Chardon E, Sultan C, Josso F. The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 1975; 30: 151-158
    CrossrefPubMedGoogle Scholar
  • 20 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a Factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
    CrossrefPubMedGoogle Scholar
  • 21 Francis JL, El-Baruni K, Roath OS, Taylor I. Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res 1988; 52: 207-217
    CrossrefPubMedGoogle Scholar
  • 22 El-Baruni K, Taylor I, Roath S, Francis JL. Factor X-activating procoagulant in normal and malignant breast tissue. Hematol Oncol 1990; 8: 323-332
    CrossrefPubMedGoogle Scholar
  • 23 Gordon SG, Lewis BJ. Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res 1978; 38: 2467-2472
    PubMedGoogle Scholar
  • 24 Gordon SG, Franks JJ, Lewis BJ. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 1979; 62: 773-776
    PubMedGoogle Scholar
  • 25 Gordon S, Sloane B, Cavanaugh P, Cross B, McLaughlin R, Honn K, Chelladurai M. Purification and characterization of two procoagulants from Walker 256 carcinosarcoma tumors. Thromb Haemostas 1987; 58 (Suppl) 235
    PubMedGoogle Scholar
  • 26 Redgrave TG, Devereux D, Deckers PJ. Hyperlipidemia in tumor-bearing rats. Biochim Biophys Acta 1984; 795: 286-292
    CrossrefPubMedGoogle Scholar
  • 27 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 28 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of Factor X activation in humans. Blood 1989; 74: 2007-2015
    PubMedGoogle Scholar
  • 29 Zacharski LR, Rosenstein R, Phillips PG. Concanavalin A inhibition of tissue factor (thromboplastin) activity. Blood 1974; 44: 783-787
    PubMedGoogle Scholar
  • 30 Gasic GJ, Gasic TB, Jimenez SA. Platelet aggregating material in mouse tumor cells. Removal and regeneration. Lab Invest 1977; 36: 413-419
    PubMedGoogle Scholar
  • 31 Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-l,5-pentanediyl) amide. Cancer Res 1981; 41: 4535-4539
    PubMedGoogle Scholar
  • 32 Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol 1981; 11: 367-378
    CrossrefPubMedGoogle Scholar
  • 33 Karpatkin S, Smerling A, Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblast. J Lab Clin Med 1980; 96: 994-1001
    PubMedGoogle Scholar
  • 34 Edwards RL, Rickles R, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359-370
    PubMedGoogle Scholar
  • 35 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-273
    PubMedGoogle Scholar
  • 36 Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Haematol 1973; 24: 89-99
    CrossrefPubMedGoogle Scholar
  • 37 Ewan VA, Edwards RL, Rickles R. Expression of procoagulant activity in a human monocyte-like cell line. J Lab Clin Med 1983; 101: 401-410
    PubMedGoogle Scholar
  • 38 Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989; 49: 5443-5447
    PubMedGoogle Scholar
  • 39 Khato J, Suzuki M, Sato H. Quantitative study in thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. Gann 1974; 65: 289-294
    PubMedGoogle Scholar
  • 40 Hilgard P, Whur P. Factor X-activating activity from Lewis lung carcinoma. Br J Cancer 1980; 41: 642-643
    CrossrefPubMedGoogle Scholar
  • 41 Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 1979; 40: 228-233
    CrossrefPubMedGoogle Scholar
  • 42 Grignani G, Falanga A, Pacchiarini L, Allessio MG, Zucchella M, Fratino P, Donati MB. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 1988; 42: 554-557
    CrossrefPubMedGoogle Scholar
  • 43 Cavanaugh PG, Sloane B, Honn KV. Role of the coagulation system in tumor-cell induced platelet aggregation and metastasis. Haemostasis 1988; 18: 37-46
    PubMedGoogle Scholar
  • 44 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-5567
    CrossrefPubMedGoogle Scholar
  • 45 Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261-1265
    PubMedGoogle Scholar
  • 46 Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46: 6471-6474
    PubMedGoogle Scholar
  • 47 Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870-875
    PubMedGoogle Scholar
  • 48 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020
    CrossrefPubMedGoogle Scholar
  • 49 Karp G, Pangasnan R, Hudzik P, Devereux D. Activation of Factor X by a rat sarcoma procoagulant. Clin Res 1991; 39: 451A
    PubMedGoogle Scholar